Pharmacological blockade of the N- and
L-type calcium channel lessens renal injury in
kidney disease patients. The significance of specific blockade of α1 subunit of
N-type calcium channel, Cav2.2, in
diabetic nephropathy, however, remains to be clarified. To examine functional roles, we mated Cav2.2(-/-) mice with db/db (diabetic) mice on the C57BLKS background. Cav2.2 was localized in glomeruli including podocytes and in distal tubular cells. Diabetic Cav2.2(-/-) mice significantly reduced urinary
albumin excretion, glomerular hyperfiltration,
blood glucose levels, histological deterioration and systolic blood pressure (SBP) with decreased urinary
catecholamine compared to diabetic Cav2.2(+/+) mice. Interestingly, diabetic heterozygous Cav2.2(+/-) mice also decreased
albuminuria, although they exhibited comparable systolic blood pressure, sympathetic nerve activity and
creatinine clearance to diabetic Cav2.2(+/+) mice. Consistently, diabetic mice with
cilnidipine, an N-/
L-type calcium channel blocker, showed a reduction in
albuminuria and improvement of glomerular changes compared to diabetic mice with
nitrendipine. In cultured podocytes, depolarization-dependent
calcium responses were decreased by ω-
conotoxin, a Cav2.2-specific inhibitor. Furthermore, reduction of
nephrin by
transforming growth factor-β (TGF-β) in podocytes was abolished with ω-
conotoxin,
cilnidipine or
mitogen-activated protein kinase kinase inhibitor. In conclusion, Cav2.2 inhibition exerts renoprotective effects against the progression of
diabetic nephropathy, partly by protecting podocytes.